Danvers, MA – September 20, 2016
Cell Signaling Technology Chief Scientific Officer, Dr. Roby Polakiewicz, will speak on two panels at the Global Biological Standards Institute (GBSI) Antibody Validation Workshop.
The workshop brings together key stakeholders from academia, antibody producers, pharma, funders, policy makers and journals to share perspectives. Together, they will build consensus and craft recommendations for tangible solutions aimed at improving accuracy in research antibody usage and validation. GBSI is a non-profit organization dedicated to improving the quality and reproducibility of biomedical research.
The conference will be held at the Asilomar Conference Grounds in Pacific Grove, CA. For more information on the workshop and panels, please visit: https://www.gbsi.org/event/asilomar/#1472055027273-9103ffc6-f639
Monday, September 26, 1:00 – 2:15 p.m. (Pacific Time)
This session will be a facilitated discussion focusing on the benefits of recombinant antibodies for use in research, including their current place in the market and how they address antibody quality and reproducibility. Other affinity reagents will also be highlighted. Dr. Polakiewicz and the panelists will share perspective on the benefits and challenges of open-access sequence information for reagents and recombinant antibodies.
Tuesday, September 27, 8:45 – 10:15 a.m. (Pacific Time)
Dr. Polakiewicz and the panelists will share perspective on current methods, needs, and consumer information-sharing practices for validation of research antibodies, measures that often fall within the QA/QC of the antibody production process. The potential role of certification of producers and service providers for antibody validation will also be highlighted. Panelists will address the role that producers and service providers play in countering or otherwise addressing issues of reproducibility in research.
To meet with Dr. Polakiewicz at GBSI, please email: firstname.lastname@example.org.
In his role as Chief Scientific Officer, Dr. Roby Polakiewicz has been responsible for Product and Technology innovation at Cell Signaling Technology (CST) since 2005. His leadership and direction have created the company’s most valuable products and valuable intellectual property. Dr. Polakiewicz has driven the successful implementation of four generations of novel antibody platform technologies that have been critical to the success of CST. Dr. Polakiewicz’s research interests span different fields including molecular and cell biology, signal transduction, and cancer. During his 25 years of experience in research and technology development, Dr. Polakiewicz has published approximately 65 peer-reviewed publications, and is a named inventor on numerous patents and patent applications.
Dr. Polakiewicz received his B.S. in Chemistry and Ph.D. in Molecular Biology from the Hebrew University of Jerusalem, and completed postdoctoral studies at the Whitehead Institute for Biomedical Research at M.I.T.
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community. Its employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. www.cellsignal.com.
The Castle Group